
|Videos|July 12, 2016
Dr. George D. Demetri on the Impact of Sarcoma Subtyping on Other Cancers
Author(s)George D. Demetri, MD
Advertisement
George D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, explains how sarcoma treatment has influenced the treatment of other cancers.
Sarcoma continues to pave the way for what is happening in other cancers, says Demetri. The disease is broken down into over 500 different subtypes, each with their own treatment specifications. This method is now being applied in lung, breast, and colorectal cancers, says Demetri.
Some cancers have also been decommissioned, and are not longer consider carcinomas at all.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































